Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest C1-inhibitor Stories

2014-03-01 12:20:36

Analysis also reveals decrease in emergency room visits and hospitalizations SAN DIEGO, March 1, 2014 /PRNewswire/ -- Findings announced by CSL Behring today show that current hereditary angioedema (HAE) treatment options, such as C1 Esterase Inhibitor (C1-INH) concentrate, are allowing for greater patient satisfaction, higher rates of home treatment and a decrease in the number of hospitalizations and visits to the emergency room. HAE is a rare, potentially fatal swelling disorder...

2014-02-20 08:32:25

International study by CSL Behring is world's first placebo-controlled phase III trial to examine subcutaneous administration of C1-INH for use in treating rare, sometimes life-threatening, condition KING OF PRUSSIA, Pa., Feb. 20, 2014 /PRNewswire/ -- CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with frequent hereditary...

2013-11-12 08:35:43

- Data presented at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting - EXTON, Pa., Nov. 12, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced results of a new quality of life data analysis from the randomized, placebo-controlled pivotal prophylaxis study of...

2013-11-11 04:21:09

Earnings accretive, revenue growth-enhancing acquisition DUBLIN and EXTON, Pennsylvania, November 11, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) and ViroPharma Incorporated (NASDAQ: VPHM) today announce that their Boards of Directors have unanimously approved, and the companies have entered into, a merger agreement pursuant to which Shire will acquire all the outstanding shares of the rare disease company ViroPharma for $50 per share in cash, for a total...

2013-11-08 08:28:06

Responding HAE specialists agree that self-administration is advantageous to patients' time, independence and convenience BALTIMORE, Nov. 8, 2013 /PRNewswire/ -- More patients with hereditary angioedema (HAE), a rare and potentially fatal genetic disorder, are being offered and opting for self-administration therapy, according to data from a new survey being presented at the 2013 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Of the HAE treatment centers...

2013-11-06 16:30:36

EXTON, Pa., Nov. 6, 2013 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced it will present data relating to the quality of life in patients with Hereditary Angioedema (HAE) receiving nanofiltered C1 Inhibitor (C1 INH-nf) replacement therapy for prophylaxis as well as data relating to the Angioedema Clinical Epidemiology Testing Initiative for the study of Hereditary Angioedema (ACET) at the 70th American College of Allergy, Asthma and Immunology (ACAAI) Annual...

2013-10-07 16:25:21

NEWARK, Del., Oct. 7, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO), a biotechnology company focused on commercializing its proprietary transformative recombinant platform technology for development and production of biologics using transient gene expression in unmodified green plants, today confirmed, as required by Section 610(b) of the NYSE MKT Company Guide, the receipt of an audit opinion for its year ended June 30, 2013, containing a going concern qualification. This...

2013-08-01 08:33:48

EXTON, Pa., Aug. 1, 2013 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that following discussion with the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food and Drug Administration, ViroPharma is going to discontinue this Phase 2 study. The discontinuation of the study is a precaution related to the emergence of an unexpected incidence and titer of non-neutralizing anti-rHuPH20 antibodies in a number of patients with the...

2013-05-28 08:28:30

- Oral Presentation at the 8th C1 Inhibitor Deficiency Workshop - EXTON, Pa., May 28, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced results of new data analyses from the randomized, placebo-controlled and open label clinical trials of Cinryze® (C1 esterase inhibitor [human]), the first and...

2013-04-16 08:29:59

Expanded label approved in 23 European countries for treatment and pre-procedure prevention of acute episodes of hereditary angioedema MARBURG, Germany, April 16, 2013 /PRNewswire/ -- CSL Behring today announced that European health authorities have approved an extended use of Berinert®, a C1-esterase inhibitor (C1-INH) concentrate, for pre-procedure prevention (short-term prophylaxis) of acute episodes of hereditary angioedema (HAE), in adult and pediatric patients undergoing...